{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:27:35Z","timestamp":1790389655894,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.neuropharm.2017.01.039","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T15:16:42Z","timestamp":1486048602000},"page":"74-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-717X","authenticated-orcid":false,"given":"Roberta","family":"Felici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Buonvicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Muzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Cavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cesaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Luceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiarugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.01.039_bib1","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.neurobiolaging.2011.06.002","article-title":"Dietary restriction but not rapamycin extends disease onset and survival of the H46R\/H48Q mouse model of ALS","volume":"33","author":"Bhattacharya","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through article mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.neuropharm.2017.01.039_bib3","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4161\/cc.7.24.7244","article-title":"Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors","volume":"7","author":"Carracedo","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2014.11.004","article-title":"Current treatment strategies for inhibiting mTOR in cancer","author":"Chiarini","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003875","article-title":"Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A\/C gene mutation","volume":"4","author":"Choi","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2013.08.032","article-title":"Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency","volume":"155","author":"Cogliati","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2125.2005.02473.x","article-title":"Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients","volume":"60","author":"Dansirikul","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10540-007-9041-4","article-title":"Mitochondrial diseases: therapeutic approaches","author":"DiMauro","year":"2007","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s13311-014-0285-y","article-title":"PARP inhibition delays progression of mitochondrial encephalopathy in mice","volume":"11","author":"Felici","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib11","doi-asserted-by":"crossref","first-page":"e76938","DOI":"10.1371\/journal.pone.0076938","article-title":"Insight into molecular and functional properties of NMNAT3 reveals new hints of NAD homeostasis within human mitochondria","volume":"8","author":"Felici","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2015.00247","article-title":"Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice","volume":"6","author":"Johnson","year":"2015","journal-title":"Front. Genet."},{"issue":"49","key":"10.1016\/j.neuropharm.2017.01.039_bib13","first-page":"377","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome","volume":"80","author":"Johnson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmet.2016.05.009","article-title":"The mechanistic target of rapamycin: the grand ConducTOR of metabolism and aging","volume":"23","author":"Kennedy","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cmet.2008.02.004","article-title":"Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy","volume":"7","author":"Kruse","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib16","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.1301005","article-title":"Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus","volume":"191","author":"Lai","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/mol.110.070110","article-title":"Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription","volume":"79","author":"Lapucci","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The Neurology of mTOR","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib20","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","volume":"172","author":"McGrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","article-title":"MTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation","volume":"18","author":"Morita","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mito.2007.02.002","article-title":"Molecular genetic and clinical aspects of mitochondrial disorders in childhood","volume":"7","author":"Moslemi","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib23","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.39791","article-title":"Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice","volume":"68","author":"Oaks","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","article-title":"Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014","volume":"23","author":"Pike","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib25","first-page":"4","volume":"107","author":"Quintana","year":"2010"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003802","article-title":"Rapamycin reverses elevated mTORC1 signaling in lamin A\/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival","volume":"4","author":"Ramos","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0090-9556(25)08793-8","article-title":"Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat","volume":"20","author":"Sattler","year":"1992","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib30","doi-asserted-by":"crossref","first-page":"27643","DOI":"10.1074\/jbc.M603536200","article-title":"The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity","volume":"281","author":"Schieke","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.02.015","article-title":"When lamins go bad: nuclear structure and disease","author":"Schreiber","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/acel.12313","article-title":"Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins","volume":"14","author":"Schreiber","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cmet.2015.05.007","article-title":"The opa1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage","volume":"21","author":"Varanita","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2017.01.039_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuron.2016.11.038","article-title":"Loss Nardilysin, a co-chaperone for \u03b1-Ketoglutarate Dehydrogenase, promotes mTORC1 activation and neurodegeneration","volume":"93","author":"Yoon","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4161\/auto.7.4.14541","article-title":"Rapamycin treatment augments motor neuron degeneration in SOD1 G93A mouse model of amyotrophic lateral sclerosis","volume":"7","author":"Zhang","year":"2011","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2017.01.039_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1997.tb04318.x","article-title":"Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration","volume":"37","author":"Zimmerman","year":"1997","journal-title":"J.\u00a0Clin. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817300400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:18:17Z","timestamp":1749943097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817300400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":36,"alternative-id":["S0028390817300400"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.039","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}